Abstract
Objective: The aim of this study is to evaluate the demographic, radiological and histopathological
findings, tumoral biomarkers, and survival rates of patients who underwent a stereotactic
brain biopsy and those diagnosed with glioblastoma, metastasis, and lymphoma, and
the changes in the diagnosis distribution over the years.
Materials and Methods: The patients who underwent stereotactic biopsy in our clinic between 2012 and 2020
were evaluated retrospectively. Metastasis, glioblastoma, and lymphoma cases were
evaluated as three main groups and the others were excluded. P53 gene expression,
isocitrate dehydrogenase (IDH) mutation, and Ki-67 values in glioblastoma cases and
Bcl-2, Bcl-6 proteins, and Ki-67 values in lymphomas and their relationship with survival
were evaluated.
Results: High p53 expression was observed in 27.5% cases diagnosed with glioblastoma. IDH
mutation was negative in all glioblastoma cases. Presence of Bcl-2 and Bcl-6 proteins
was not associated with survival in lymphomas. Survival rate was significantly higher
in cases diagnosed with lymphoma (26.9%) compared to those diagnosed with glioblastoma.
A statistically significant increase was determined in patients diagnosed with lymphoma
considering the distribution of diseases and incidence and in the distribution of
other diagnoses over the years (p < 0.05).
Conclusion: As per the distribution of the disease in recent times, it has been observed that
there is an increase in lymphoma cases. Histopathology and biomarkers have great importance
in the diagnosis and treatment of cerebral lesions. We think that our findings will
be supported by studies in which larger patient population and detailed biomarkers
will be studied.
Keywords
stereotactic brain biopsy - primary central nervous system lymphomas - glioblastoma
- cerebral metastasis
